Dogra Kanchan, Fulzele Parag, Rout Diptiranjan, Chaurasia Rahul, Coshic Poonam, Chatterjee Kabita
Department of Transfusion Medicine, AIIMS, New Delhi, India.
Indian J Hematol Blood Transfus. 2017 Mar;33(1):106-108. doi: 10.1007/s12288-016-0681-z. Epub 2016 May 19.
Apheretic platelets are better quality blood components which reduce donor exposure and chances of TTIs to transfusion recipients when compared to the whole blood derived components. Though safe, these apheretic donations are associated with donor adverse events. We evaluated the incidence of such adverse events associated with the modern apheresis procedures that would provide an insight as well as help formulating preventive steps to avoid frequent occurrences of such events. This prospective audit-based observational study was conducted over 1 year. Donors for plateletpheresis were selected as per the standard operating procedure of the Apheresis Lab. The apheresis procedures were done on the MCS+ (Haemonetics Corp.), Trima Accel (Terumo BCT) and COM.TEC (Fresenius Kabi AG). 1740 apheresis procedures were performed, out of which 1708 were plateletpheresis and 32 therapeutic plasma exchange (TPE) procedures for 7 patients. A total of 102 adverse events were noted; of which, 80 (78.43 %) events were associated with donors, 15 (14.71 %) were owed to equipment related problems and 7 (6.86 %) were technical aberrations. All the events associated with donors were mild. No adverse events were reported with any of the 32 TPEs. Apheresis procedures are associated with adverse events which can be reduced by meticulous donor-vigilance, superior training modules for the technical personnel and continued supervision of experienced transfusion medicine specialists. Continued efforts towards making the donor's experience with apheresis more pleasant give a forward thrust to the noble vision of preparing a voluntary apheresis donor pool in India.
与全血来源的成分相比,单采血小板是质量更好的血液成分,可减少供血者暴露以及输血受者发生输血传播感染的几率。尽管这些单采成分是安全的,但与供血者不良事件有关。我们评估了与现代单采程序相关的此类不良事件的发生率,这将有助于深入了解并有助于制定预防措施,以避免此类事件频繁发生。这项基于前瞻性审核的观察性研究进行了1年。根据单采实验室的标准操作程序选择血小板单采供血者。单采程序在MCS+(美国血液技术公司)、Trima Accel(日本泰尔茂集团下属BCT公司)和COM.TEC(费森尤斯卡比股份公司)设备上进行。共进行了1740次单采程序,其中1708次是血小板单采,7名患者进行了32次治疗性血浆置换(TPE)程序。共记录到102起不良事件;其中,80起(78.43%)事件与供血者有关,15起(14.71%)归因于设备相关问题,7起(6.86%)是技术偏差。所有与供血者相关的事件均为轻度。32次TPE程序均未报告不良事件。单采程序与不良事件有关,通过细致的供血者监测、为技术人员提供优质培训模块以及经验丰富的输血医学专家持续监督,可以减少这些不良事件。持续努力让供血者在单采过程中有更愉快的体验,有助于推动在印度建立自愿单采供血者库这一崇高愿景的实现。